Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Assessment of Low-dose ASA Discontinuation Risk Associated With Concomitant PPI Use During the First Year of ASA Therapy

Completed

Conditions: Cardiovascular Prevention

Interventions: Drug: Risk of low dose aspirin discontinuation

First Posted Date: 2013-06-28

Last Posted Date: 2014-05-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 35604

Registration Number: NCT01888575

Locations: 🇪🇸
Research Site, Madrid, Spain

Risk of Uncomplicated Peptic Ulcer in the General Population

Completed

Conditions: Peptic Ulcer [Iowa Type (107680.0010)]

Interventions: Drug: Risk of symptomatic peptic ulcer

First Posted Date: 2013-06-28

Last Posted Date: 2014-07-15

Lead Sponsor: AstraZeneca

Target Recruit Count: 4000

Registration Number: NCT01888588

Locations: 🇪🇸
Research Site, Madrid, Spain

Cardiovascular Risk Stratification of Ambulatory Patients in Primary Prevention

Completed

Conditions: Cardiovascular Primary Prevention

First Posted Date: 2013-06-28

Last Posted Date: 2014-07-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 516

Registration Number: NCT01889030

Locations: 🇦🇷
Research Site, Buenos Aires, Argentina

Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.

Phase 1

Completed

Conditions: Bioavailability Heathy Volunteers

Interventions: Drug: Ticagrelor 90 mg whole tablet
Drug: Ticagrelor 90 mg tablet crushed
Drug: Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube

First Posted Date: 2013-06-27

Last Posted Date: 2013-09-18

Lead Sponsor: AstraZeneca

Target Recruit Count: 36

Registration Number: NCT01887626

Locations: 🇬🇧
Research Site, London, United Kingdom

Prevalence and Risk Factors in Unipolar Depression Patients Without Remission After One Antidepressant Trial

Completed

Conditions: Non-psychotic Unipolar Major Depression

First Posted Date: 2013-06-27

Last Posted Date: 2015-07-30

Lead Sponsor: AstraZeneca

Target Recruit Count: 200

Registration Number: NCT01887639

Locations: 🇦🇷
Research Site, Tucuman, Argentina

AZD8186 First Time In Patient Ascending Dose Study

Phase 1

Completed

Conditions: Triple Negative Breast Cancer TNBC
Squamous Non-Small Cell Lung Cancer sqNSCLC
Advanced Castrate-resistant Prostate Cancer CRPC

Interventions: Drug: Part D2 AZD2014 combination with AZD8186

First Posted Date: 2013-06-24

Last Posted Date: 2020-05-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 147

Registration Number: NCT01884285

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Phase 3

Completed

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)

Interventions: Drug: Placebo
Drug: Linaclotide

First Posted Date: 2013-06-19

Last Posted Date: 2016-09-27

Lead Sponsor: AstraZeneca

Target Recruit Count: 1722

Registration Number: NCT01880424

Locations: 🇳🇿
Research Site, Wellington, New Zealand

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: exenatide

First Posted Date: 2013-06-13

Last Posted Date: 2015-02-24

Lead Sponsor: AstraZeneca

Target Recruit Count: 275

Registration Number: NCT01876849

Locations: 🇺🇸
Research Site, Renton, Washington, United States

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Phase 3

Active, not recruiting

Conditions: Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Platinum Sensitive
BRCA Mutated

Interventions: Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

First Posted Date: 2013-06-11

Last Posted Date: 2025-04-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 327

Registration Number: NCT01874353

Locations: 🇺🇸
North Shore University, Evanston, Illinois, United States
🇨🇦
Sunnybrook Health Sciences Center, Toronto, Ontario, Canada
🇨🇳
West China Hospital Affiliated to Sichuan University, Chengdu, China

and more 122 locations

A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction

Not Applicable

Completed

Conditions: Myocardial Infarction

Interventions: Device: Mobile-phone based patient support
Device: e-diary

First Posted Date: 2013-06-11

Last Posted Date: 2016-02-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 174

Registration Number: NCT01874262

Locations: 🇸🇪
Research Site, Vaxjo, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy